Detail akcie China Shineway Pharmaceutical Group Ltd, Ordinary, Frankfurt Stock Exchange online

Business Summary: China Shineway Pharmaceutical Group Ltd is an investment holding company primarily engaged in research and development, manufacturing and trading of Chinese pharmaceutical products. The Company’s product dosage forms include injections, soft capsules, granules, traditional Chinese medicine (TCM) granules, oral products and other dosage forms. The Company’s products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, Compound Licorice Tablet and other products, applied to influenza, cardio-cerebrovascular, respiratory system and other disease fields. The Company operates its business in mainland China and Hong Kong markets.
Financial Summary: BRIEF: For the six months ended 30 June 2025, China Shineway Pharmaceutical Group Ltd revenues decreased 21% to RMB1.65B. Net income decreased 2% to RMB614.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects G/L on Sale of Tangible & Intangible FA increase from RMB255K to RMB7.6M (expense), Research and development costs increase of 13% to RMB50.4M (expense).